Parker Research Institute Report issue

Academic/Hospital Phase 4
Founded: San Francisco California United States (2016)

Organization Overview

First Clinical Trial
2016
NCT02928679
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2016

Timeline

NOW
  • Now

Alternative names

Henrik Gudbergsen | Parker Research Institute